Multidrug-resistant Acinetobacter baumannii bacteraemia: Clinical features, antimicrobial therapy and outcome

Clinical Microbiology and Infection

Volumn 13, Issue 2, 2007, Pages 196-198

  Kuo, L C ^a   Lai, C C ^a   Liao, C H ^a   Hsu, C K ^a   Chang, Y L ^a   Chang, C Y ^a   Hsueh, P R ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Acinetobacter baumannii; Antimicrobial therapy; Bacteraemia; Mortality; Multidrug resistance; Resistance

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIN; DOXYCYCLINE; GENTAMICIN; IMIPENEM; MEROPENEM; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULTAMICILLIN; TIGECYCLINE; TIMENTIN;

ACINETOBACTER BAUMANNII; ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; CATHETER INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; CHILD; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANCE; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; URINARY TRACT INFECTION; WOUND INFECTION;

ACINETOBACTER BAUMANNII;

EID: 33846332693     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01601.x     Document Type: Article

References (21)

1. Allen DM, Hartman BJ. Acinetobacter species. In: Mandell GL, Bennett GE, Dolin R, eds, Mandell, Douglas and Bennett's principles and practice of infectious diseases, 5th edn. Edinburgh: Churchill Livingstone, 2000; 2339-2343.
2. Hirai Y. Survival of bacteria under dry conditions: From a viewpoint of nosocomial infection. J Hosp Infect 1991; 19: 191-200.
3. Larson EL. Persistent carriage of gram-negative bacteria on hands. Am J Infect Control 1981; 9: 112-119.
4. Rosenthal S, Tager IB. Prevalence of gram-negative rods in the normal pharyngeal flora. Ann Intern Med 1975; 83: 355-357.
5. Wendt C, Dietze B, Dietz E, Ruden H. Survival of Acinetobacter baumannii on dry surfaces. J Clin Microbiol 1997; 35: 1394-1397.
6. Seifert H, Strate A, Pulverer G. Nosocomial bacteraemia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Medicine (Baltimore) 1995; 74: 340-349.
7. Smolyakov R, Borer A, Riesenberg K et al. Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: Risk factors and outcome with ampicillin-sulbactam treatment. J Hosp Infect 2003; 54: 32-38.
8. Corbella X, Ariza J, Ardanuy C et al. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother 1998; 42: 793-802.
9. Choi JY, Park YS, Cho CH et al. Synergic in-vitro activity of imipenem and sulbactam against Acinetobacter baumannii. Clin Microbiol Infect 2004; 10: 1098-1101.
10. Jimenez-Mejias ME, Pachon J, Becerril B, Palomino-Nicas J, Rodriguez-Cobacho A, Revuelta M. Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam. Clin Infect Dis 1997; 24: 932-935.
11. Landman D, Quale JM, Mayorga D et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: The pre-antibiotic era has returned. Arch Intern Med 2002; 162: 1515-1520.
12. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006; 12: 826-836.
13. Hsueh PR, Teng LJ, Chen CY et al. Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis 2002; 8: 827-832.
14. Kuo LC, Yu CJ, Lee LN et al. Clinical features of pandrug-resistant Acinetobacter baumannii bacteraemia at a university hospital in Taiwan. J Formos Med Assoc 2003; 102: 601-606.
15. Kuo LC, Teng LJ, Yu CJ, Ho SW, Hsueh PR. Dissemination of a clone of unusual phenotype of pandrug-resistant Acinetobacter baumannii at a university hospital in Taiwan. J Clin Microbiol 2004; 42: 1759-1763.
16. Clinical Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests; approved standard, 9th edn. Wayne, PA: CLSI, 2006.
17. Cisneros JM, Reyes MJ, Pachon J et al. Bacteraemia due to Acinetobacter baumannii: Epidemiology, clinical findings and prognostic features. Clin Infect Dis 1996; 22: 1026-1032.
18. Ko WC, Lee HC, Chiang SR et al. In-vitro and in-vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain. J Antimicrob Chemother 2004; 53: 393-395.
19. Savov E, Chankova D, Vatcheva R, Dinev N. In-vitro investigation of the susceptibility of Acinetobacter baumannii strains isolated from clinical specimens to ampicillin/sulbactam alone and in combination with amikacin. Int J Antimicrob Agents 2002; 20: 390-392.
20. Cisneros JM, Rodriguez-Bano J. Nosocomial bacteraemia due to Acinetobacter baumannii: Epidemiology, clinical features and treatment. Clin Microbiol Infect 2002; 8: 687-693.
21. Levin AS, Barone AA, Penco J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008-1011.